Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Can Genentech’s $50 direct-to-patient Xofluza launch reshape access to flu antivirals in 2025? Genentech slashes Xofluza price by 70% in a direct-to-patient launch with Amazon, Cost Plus, and Alto Pharmacy. See how this reshapes flu access in 2025. bySrinathOctober 16, 2025